Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting

Table 2 Therapeutic agents targeting the integrin αIIbβ3 molecule in clinical use and preclinical studies

Class	Agent	Synonyms	Status	References
Monoclonal antibody	Abciximab	ReoPro, Clotinab, CentoRx	Approved	[230]
Monoclonal antibody	YM337	Null	No development reported	[258]
KGD sequence	Eptifibatide	Intrifiban, SB-1, Sch-60936, Integrilin	Approved	[232]
RGD sequence	MK-0852	L-367073	No development reported	[259]
	G4120	Null	No development reported	[260]
	DMP-728	Null	No development reported	[261]
Nonpeptide inhibitors	Tirofiban	L-700462, MK-383, Aggrastat	Approved	[262]
	Lamifiban	Ro-449883	Not approved	[263]
	GR144053	Null	No development reported	[264]
Oral agents	Xemilofiban	SC-54684; SC-54701 is the active component of xemilofiban	Not approved	[265]
	Orbofiban	SC-57099B, CS-511; SC-57101 is the active component of orbofiban	Not approved	[266]
	Sibrafiban	Null	Not approved	[267]
	Lotrafiban	Null	Not approved	[268]
	Lefradafiban	BiBu-104; fradafiban is the active component of lefradafiban	Not approved	[238]
	Roxifiban	DMP754	Not approved	[269]
	Cromafiban	CT-50352	Not approved	[238]
	FK-633	Null	Not approved	[238]
	Elarofiban	RWJ-53308	Not approved	[238, 270]
	SR-121787	Null	Not approved	[238, 271]
	Alnidofibatide	PRP-109891, Klerval	Not approved	[272]
Others	ANTP266	Null	Preclinical studies	[246]
	RUC-1, RUC-2	Null	Preclinical studies	[273, 274]
	PLT/uPA-T	Null	Preclinical studies	[244]
	scFvSCE5-scuPA	Null	Preclinical studies	[243]
	Targ-CD39	Null	Preclinical studies	[275]
	myr-FEEERA	Null	Preclinical studies	[181]
	RGT-containing peptides	Null	Preclinical studies	[196, 197]

ISSN: 1756-8722